Literature DB >> 12473103

Complexation of ytterbium to human transferrin and its uptake by K562 cells.

Xiu-Lian Du1, Tian-Lan Zhang, Lan Yuan, Yong-Yuan Zhao, Rong-Chang Li, Kui Wang, Siu Cheong Yan, Li Zhang, Hongzhe Sun, Zhong-Ming Qian.   

Abstract

There is an increasing interest in the use of lanthanides in medicine. However, the mechanism of their accumulation in cells is not well understood. Lanthanide cations are similar to ferric ions with regard to transferrin binding, suggesting transferrin-receptor mediated transport is possible; however, this has not yet been confirmed. In order to clarify this mechanism, we investigated the binding of Yb3+ to apotransferrin by UV-Vis spectroscopy and stopped-flow spectrophotometry, and found that Yb3+ binds to apotransferrin at the specific iron sites in the presence of bicarbonate. The apparent binding constants of these sites showed that the affinity of Yb3+ is lower than that of Fe3+and binding of Yb3+ in the N-lobe is kinetically favored while the C-lobe is thermodynamically favored. The first Yb3+ bound to the C-lobe quantitatively with a Yb/apotransferrin molar ratio of < 1, whereas the binding to the other site is weaker and approaches completeness by a higher molar ratio only. As demonstrated by 1H NMR spectra, Yb3+ binding disturbed the conformation of apotransferrin in a manner similar to Fe3+. Flow cytometric studies on the uptake of fluorescein isothiocyanate labeled Yb3+-bound transferrin species by K562 cells showed that they bind to the cell receptors. Laser scanning confocal microscopic studies with fluorescein isothiocyanate labeled Yb3+-bound transferrin and propidium iodide labeled DNA and RNA in cells indicated that the Yb3+ entered the cells. The Yb3+-transferrin complex inhibited the uptake of the fluorescein labeled ferric-saturated transferrin (Fe2-transferrin) complex into K562 cells. The results demonstrate that the complex of Yb3+-transferrin complex was recognized by the transferrin receptor and that the transferrin-receptor-mediated mechanism is a possible pathway for Yb3+ accumulation in cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12473103     DOI: 10.1046/j.1432-1033.2002.03326.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  6 in total

1.  Uptake of diterbium transferrin, a potential multi-photon-excited microscopy probe, into human leukemia K562 cells via a transferrin-receptor-mediated process.

Authors:  Lan Yuan; Ping Du; Kui Wang; Xiao-Gai Yang
Journal:  J Biol Inorg Chem       Date:  2009-07-15       Impact factor: 3.358

2.  Receptor recognition of transferrin bound to lanthanides and actinides: a discriminating step in cellular acquisition of f-block metals.

Authors:  Gauthier J-P Deblonde; Manuel Sturzbecher-Hoehne; Anne B Mason; Rebecca J Abergel
Journal:  Metallomics       Date:  2013-06       Impact factor: 4.526

3.  Sensitizing curium luminescence through an antenna protein to investigate biological actinide transport mechanisms.

Authors:  Manuel Sturzbecher-Hoehne; Christophe Goujon; Gauthier J-P Deblonde; Anne B Mason; Rebecca J Abergel
Journal:  J Am Chem Soc       Date:  2013-02-11       Impact factor: 15.419

4.  Preparation, Biological Evaluation and Dosimetry Studies of 175Yb-Bis-Phosphonates for Palliative Treatment of Bone Pain.

Authors:  Ashraf Fakhari; Amir R Jalilian; Hassan Yousefnia; Saeed Shanehsazzadeh; Ali Bahrami Samani; Fariba Johari Daha; Mehdi Shafiee Ardestani; Ali Khalaj
Journal:  Mol Imaging Radionucl Ther       Date:  2015-10-05

5.  Quantification and Assessment of the Chemical Form of Residual Gadolinium in the Brain After Repeated Administration of Gadolinium-Based Contrast Agents: Comparative Study in Rats.

Authors:  Thomas Frenzel; Chirag Apte; Gregor Jost; Laura Schöckel; Jessica Lohrke; Hubertus Pietsch
Journal:  Invest Radiol       Date:  2017-07       Impact factor: 6.016

6.  Production, Quality Control and Pharmacokinetic Studies of (177)Lu-EDTMP for Human Bone Pain Palliation Therapy Trials.

Authors:  Ali Bahrami-Samani; Akbar Anvari; Amir Reza Jalilian; Simindokht Shirvani-Arani; Hassan Yousefnia; Mahmoud Reza Aghamiri; Mohammad Ghannadi-Maragheh
Journal:  Iran J Pharm Res       Date:  2012       Impact factor: 1.696

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.